CORT:NASDAQ
Corcept Therapeutics Inc
$80.46
arrow_downward
-0.81%(-0.66) 1D
$80.05
arrow_downward
-0.51% (-0.41)bedtimeAfter hours
Closed: Nov 2, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CORT...
Open
$80.93
High
$82.23
Low
$79.40
Mkt. cap
8.70B
Avg. vol.
942.16K
Volume
0.00
P/E ratio
188.85
52-wk high
$126.38
52-wk low
$28.66
EPS
$0.43
Beta
0.40
Shares outstanding
108.10M
No. of employees
730
Open
$80.93
High
$82.23
Low
$79.40
Mkt. cap
8.70B
Avg. vol.
942.16K
Volume
0.00
P/E ratio
188.85
52-wk high
$126.38
52-wk low
$28.66
EPS
$0.43
Beta
0.40
Shares outstanding
108.10M
No. of employees
730
News stories
From web sources and news partners
Investing.com
·
19 minutes ago
STARTRADER Spotlights ANTHUSD Pre-IPO CFD as Anthropic Files to List on Nasdaq By FinanceWire
Yahoo Finance
·
1 hour ago
Stock Market: Will S&P 500 Open Up or Down Today?
Financial Times
·
1 hour ago
A new threat to the New York-based stock exchanges
Bloomberg.com
·
10 hours ago
Nasdaq 100 Enters Correction as Megacap Results Amplify AI Fears
Profile
Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD. Wikipedia
About Corcept Therapeutics Inc
CEO-
Employees730
FoundedMay 13, 1998
HeadquartersMenlo Park, California, United States
SectorPharmaceutical industry
Websitecorcept.com